AbCellera Biologics (ABCL) Return on Invested Capital (2021 - 2025)

AbCellera Biologics' Return on Invested Capital history runs 5 years deep, the most recent figure standing at 0.14% for Q4 2025.

• Quarterly Return on Invested Capital fell 12.0% year-over-year to 0.14% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.14% (down 12.0% YoY) and the FY2024 annual result came in at 0.09%, down 5.0% from the prior year.
• Return on Invested Capital was 0.14% for Q4 2025 at AbCellera Biologics, down from 0.08% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.03% in Q1 2022 and bottomed at 0.14% in Q4 2025.
• A 5-year average of 0.02% and a median of 0.01% in 2024 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2024 — Return on Invested Capital changed 0 bps — and 2025, when it fell 12 bps.
• AbCellera Biologics' Return on Invested Capital stood at 0.03% in 2021, then slumped by 56 bps to 0.01% in 2022, then sank by 189 bps to 0.01% in 2023, then tumbled by 111 bps to 0.02% in 2024, then plunged by 560 bps to 0.14% in 2025.
• Business Quant data shows ABCL's Return on Invested Capital at 0.14% in Q4 2025, 0.08% in Q3 2025, and 0.05% in Q2 2025.